10058-F4: Unveiling c-Myc-Max Inhibition in DNA Repair and Telomerase Regulation

Introduction

Ongoing advances in cancer biology and stem cell research have highlighted the critical role of transcription factors and DNA repair machinery in cellular fate decisions. Among these, the proto-oncogene c-Myc functions as a master regulator of cell proliferation, metabolism, and apoptosis. Dysregulation of c-Myc and its obligate partner Max is a hallmark of many malignancies, driving unchecked cell growth and survival. In parallel, telomerase activity—governed by the expression of the telomerase reverse transcriptase (TERT) gene—underpins both tumorigenesis and stem cell maintenance, with its regulation closely intertwined with DNA repair pathways. In this context, 10058-F4, a small-molecule, cell-permeable c-Myc-Max dimerization inhibitor, has emerged as a powerful tool to dissect these complex networks. This article delivers an in-depth exploration of 10058-F4, focusing on its mechanistic impact not only in canonical apoptosis research but also in the emerging intersection of c-Myc inhibition, DNA repair, and telomerase regulation—integrating recent findings on TERT expression control.

Mechanism of Action of 10058-F4: Disrupting the c-Myc/Max Heterodimer and Transcriptional Programs

10058-F4 [(5E)-5-[(4-ethylphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one] is a well-characterized small-molecule c-Myc inhibitor (MW 249.35) uniquely designed to target the protein-protein interface between c-Myc and Max. This interaction is essential for c-Myc’s function as a transcription factor, enabling it to bind DNA at E-box motifs and modulate gene expression involved in cell cycle progression, metabolism, and apoptosis. By selectively preventing c-Myc-Max heterodimerization, 10058-F4 interrupts the c-Myc/Max heterodimer disruption pathway, thereby blocking c-Myc’s access to genomic regulatory elements.

The biochemical consequences of this inhibition are profound: 10058-F4 exposure leads to a reduction in c-Myc mRNA and protein levels, suppression of downstream c-Myc-driven transcriptional programs, and induction of cell cycle arrest. Notably, this disruption triggers the mitochondrial apoptosis pathway, characterized by the modulation of Bcl-2 family proteins and cytochrome C release—hallmarks of intrinsic apoptosis. As a cell-permeable c-Myc inhibitor for apoptosis research, 10058-F4 is highly suitable for dissecting oncogenic signaling cascades at both molecular and cellular levels.

Advanced Applications: Linking c-Myc Inhibition to DNA Repair and Telomerase Regulation

c-Myc and Genome Stability: Connecting the Dots

While the traditional focus of 10058-F4 research has centered on its ability to induce apoptosis and suppress tumor cell proliferation, emerging evidence suggests that c-Myc also plays critical roles in DNA replication stress responses and genome stability. c-Myc overexpression can promote DNA damage by driving unscheduled DNA replication and impairing repair mechanisms, including those involving apurinic/apyrimidinic endodeoxyribonuclease (APE2/APEX2), as highlighted in a recent pivotal study (Stern et al., 2024).

This study demonstrated that APEX2 is indispensable for efficient TERT gene expression in human embryonic stem cells and melanoma cells. Notably, APEX2 was shown to bind near mammalian-wide interspersed repeats (MIRs) within the TERT locus, facilitating DNA repair and maintaining transcriptional competence. This finding opens new avenues for research—especially considering that c-Myc is known to regulate numerous DNA repair genes and may influence APEX2-mediated processes.

10058-F4 as a Probe for c-Myc-Driven DNA Repair and TERT Regulation

By inhibiting c-Myc/Max heterodimerization, 10058-F4 offers a unique opportunity to investigate how c-Myc activity interfaces with the cellular DNA repair landscape and TERT expression. For example, treatment with 10058-F4 could be leveraged to:

• Assess changes in APEX2 expression and localization in response to c-Myc inhibition.
• Determine the impact of c-Myc suppression on TERT mRNA and telomerase activity, particularly in stem cells and cancer models reliant on telomerase for immortality.
• Interrogate how c-Myc-driven transcriptional networks intersect with repetitive DNA element stability and repair, as suggested by the enrichment of APEX2 binding at MIR sequences in TERT intron 2.

Such experiments could illuminate novel regulatory circuits at the nexus of oncogenic transcription factor activity, DNA repair, and telomere maintenance—a conceptual advance beyond the established use of 10058-F4 in apoptosis assay development.

Preclinical Evidence: Efficacy in Hematological and Prostate Cancer Models

Acute Myeloid Leukemia Research and Mitochondrial Apoptosis

10058-F4 has been extensively validated in acute myeloid leukemia research. In cell lines such as HL-60, U937, and NB-4, 10058-F4 induces robust, dose-dependent apoptosis, with significant effects observed at 100 μM after 72 hours—correlating with diminished c-Myc levels and activation of the mitochondrial apoptosis pathway. These findings position 10058-F4 as an invaluable tool for dissecting the c-Myc/Max heterodimer disruption pathway in hematological malignancies and for the development of new targeted therapies.

Prostate Cancer Xenograft Model: In Vivo Insights

Beyond in vitro studies, intravenous administration of 10058-F4 in SCID mice bearing human prostate cancer xenografts (DU145, PC-3) resulted in measurable tumor growth inhibition, albeit with variable efficacy across models. This highlights both the promise and the complexity of c-Myc transcription factor inhibition in solid tumor contexts. The solubility profile of 10058-F4 (≥24.9 mg/mL in DMSO, ≥2.64 mg/mL in ethanol; insoluble in water) and its need for prompt use after solution preparation underscore the importance of careful formulation for translational research.

Comparative Analysis with Alternative Approaches and Content Landscape

Existing literature has explored the mechanistic underpinnings and broad applications of 10058-F4 in apoptosis and cancer biology. For example, the article "10058-F4: Advanced Applications of a c-Myc-Max Dimerizati..." surveys the compound's utility in apoptosis research but primarily emphasizes conventional pathways. In contrast, our present analysis expands upon this by integrating how c-Myc-Max inhibition via 10058-F4 may intersect with emerging DNA repair and telomerase regulatory networks, as suggested by recent findings on APEX2 and TERT.

Similarly, while "10058-F4: Novel Insights into c-Myc Inhibition and Mitoch..." discusses mitochondrial apoptosis and potential DNA repair links, our article provides a deeper focus on mechanistic cross-talk with telomerase regulation, specifically highlighting the implications of c-Myc inhibition for TERT transcription and repeat DNA element stability—a nuanced perspective not previously covered in depth.

Moreover, recent work such as "10058-F4: A Next-Generation c-Myc-Max Dimerization Inhibi..." touches upon telomerase regulation but does not analyze the direct experimental potential of using 10058-F4 alongside APEX2 and TERT modulation in stem cell and cancer models. Our article thus fills this critical gap by offering actionable research directions at the intersection of c-Myc inhibition, DNA repair, and telomere biology.

Practical Considerations for Laboratory Use

For researchers aiming to leverage 10058-F4 in advanced studies, it is essential to consider its physicochemical properties and handling requirements:

• Solubility: ≥24.9 mg/mL in DMSO; ≥2.64 mg/mL in ethanol; insoluble in water.
• Formulation: Supplied as a solid; prepare fresh solutions for immediate use. Avoid long-term storage of solutions; store the solid at -20°C.
• Experimental Design: Optimize concentrations and exposure durations based on cell type and assay (e.g., 100 μM for 72 hours in AML cell lines).

These practical guidelines ensure the reliability and reproducibility of results in both apoptosis assays and emerging DNA repair or telomerase modulation protocols.

Conclusion and Future Outlook

10058-F4 stands at the forefront of chemical biology as a highly selective c-Myc-Max dimerization inhibitor. While its established role in apoptosis induction and oncogenic pathway dissection is well recognized, this article has uniquely highlighted its potential to probe the intricate interplay between c-Myc activity, DNA repair machinery (such as APEX2), and telomerase regulation. The recent discovery that APEX2 governs TERT expression in human embryonic stem cells (Stern et al., 2024) opens new research frontiers—enabling sophisticated studies on how c-Myc inhibition with 10058-F4 might modulate genome stability, telomere maintenance, and therapeutic responses in cancer and regenerative medicine.

As the scientific community continues to unravel the multi-layered regulation of cell fate, compounds like 10058-F4 will be instrumental not only in apoptosis research but also in bridging our understanding of transcription factor control, DNA repair, and telomere biology. Future work integrating 10058-F4 with advanced genomics, proteomics, and functional assays promises to yield transformative insights—and potentially new therapeutic avenues—in both oncology and stem cell science.